Clindamycin
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Clindamycin: From Bacterial Infections to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Clindamycin is a lincosamide antibiotic that inhibits the bacterial 50S ribosome and is used against susceptible bacterial infections. The TxGNN model predicts it may be effective for punctate epithelial keratoconjunctivitis, but there are 0 clinical trials and 0 publications supporting this specific prediction. This is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (the license records provided list no indication text) |
| Predicted New Indication | Punctate epithelial keratoconjunctivitis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Clindamycin blocks bacterial protein synthesis by binding the 50S ribosomal subunit. It mainly covers Gram-positive organisms and anaerobes. The Evidence Pack does not include a detailed DrugBank mechanism entry beyond this class-level description.
The predicted indication is a poor mechanistic fit. Punctate epithelial keratitis is usually viral or toxic/inflammatory, and an antibacterial has no clear therapeutic link to it. The high score of 99.97% is not backed by any trial or publication, so it most likely reflects graph-level similarity rather than a real efficacy signal.
Two other predictions in the pack are worth noting. Exposure keratitis (score 99.80%) has a plausible but indirect link, since secondary bacterial infection is possible and clindamycin covers S. aureus. However, none of the retrieved papers tested clindamycin in that condition, and topical ocular clindamycin is not an established regimen. The other predictions (non-human animal disease, neurotrophic keratopathy, epidemic keratoconjunctivitis, postmenopausal atrophic vaginitis) show no meaningful evidence or mechanistic support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Clindamycin has 20 US authorizations in total. The main ones are below, and the records provided do not include approved indication text.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA090902 | Clindamycin Palmitate Hydrochloride | Granule, for solution | Bryant Ranch Prepack |
| ANDA065061 | Clindamycin hydrochloride | Capsule | Proficient Rx LP |
| ANDA090108 | Clindamycin | Injection, solution | Medical Purchasing Solutions, LLC |
| ANDA064050 | Clindamycin Phosphate | Solution | Bryant Ranch Prepack |
| NDA050441 | CLEOCIN PHOSPHATE | Injection, solution | Henry Schein, Inc. |
Available routes across all licenses are oral, injectable, topical (cream) and other. No ophthalmic formulation appears, and route compatibility for the predicted indication has not been assessed.
Safety Considerations
- Drug Interactions: No interaction records were found in the database query.
- Clostridioides difficile risk: The literature retrieved for another prediction describes clindamycin as a known risk factor for C. difficile infection.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-only (L5) with no supporting trials or literature. The antibacterial mechanism has no clear link to a viral or toxic/inflammatory keratitis. Of the six predictions in the pack, exposure keratitis is the only one with a plausible link, and it could be raised as a research question rather than a development candidate.
To proceed, the following is needed:
- Package insert warnings and contraindications, which are needed before safety screening
- Mechanism of action data from DrugBank
- Preclinical or clinical evidence that clindamycin acts on the etiology of punctate epithelial keratoconjunctivitis
- An ophthalmic formulation and route-compatibility assessment
- Clarification of the original indication, since the license records list none
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.